FDA Widens Type D Meetings, Narrows INTERACT Use

FDA has finalized the guidance that governs how drug and biologic sponsors get formal meetings with the agency, publishing the final version on 13 August 2026 nearly three years after the draft. The document is procedural rather than scientific, but its rules decide when a sponsor can get FDA's attention, how fast, and on what terms — and two changes from the draft narrow one popular meeting type just as another gets more room to work with.

A three-year-old draft, finally locked in

The formal-meetings guidance is one of the more heavily used documents in FDA's library, because it is the rulebook for the single highest-leverage interaction a sponsor has with the agency: a scheduled meeting where FDA commits, in writing and on the record, to a position on a development question. FDA last rewrote it in December 2017. The draft that became today's final version went out for comment on 22 September 2023, arriving alongside FDA's PDUFA VII commitments and introducing Type D meetings and a widened INTERACT program to formalize practices the agency had been running informally. Nearly three years of use — and, evidently, enough friction on two specific points — produced the edits FDA has now locked in.

Type D gets room for follow-up

Type D was built as PDUFA VII's fast lane: a meeting limited to no more than roughly two focused topics, needing input from about three FDA disciplines at most, with a much shorter response clock than a Type B or C meeting. The tradeoff for speed was scope — sponsors could not use Type D as a catch-all. The final guidance loosens that constraint in one specific way: a focused follow-up question on something FDA and the sponsor already discussed in an earlier meeting now qualifies as an appropriate Type D topic. For a sponsor who got partial clarity in a Type B meeting and needs one more narrow point resolved before finalizing a protocol, that is a materially faster path than waiting for the next major-milestone meeting.

INTERACT gets a sequencing rule

INTERACT meetings — Initial Targeted Engagement for Regulatory Advice on CDER and CBER producTs — exist for early, pre-IND-stage questions, before a sponsor has enough data for a full pre-IND meeting. The 2023 draft left the boundary between INTERACT and later meeting types somewhat open to sponsor judgment. The final guidance closes that gap: FDA now states directly that an INTERACT meeting is not appropriate for a sponsor that has already held a pre-IND meeting or a Type C meeting on the product in question. Practically, that forecloses a pattern some sponsors used INTERACT for — a lower-friction re-engagement after a formal meeting had already happened — and pushes that later-stage question back toward the meeting type built for it, typically Type B or Type C.

What carries over

The core architecture is unchanged: Type A meetings for critical, time-sensitive issues such as clinical holds or Complete Response Letter follow-up; Type B meetings for major development milestones like end-of-phase-2 and pre-NDA/BLA discussions; Type C for other formal matters that do not fit A or B; and Type D for the narrow, fast-turnaround questions PDUFA VII created. FDA also made editorial changes throughout the document “to improve clarity,” according to the agency's own characterization of the revision, on top of the two substantive changes to Type D and INTERACT.